AR088121A1 - Derivados de 4-(5-ciano-pirazol-1-il)-piperidina como moduladores de gpr119 - Google Patents

Derivados de 4-(5-ciano-pirazol-1-il)-piperidina como moduladores de gpr119

Info

Publication number
AR088121A1
AR088121A1 ARP110104351A ARP110104351A AR088121A1 AR 088121 A1 AR088121 A1 AR 088121A1 AR P110104351 A ARP110104351 A AR P110104351A AR P110104351 A ARP110104351 A AR P110104351A AR 088121 A1 AR088121 A1 AR 088121A1
Authority
AR
Argentina
Prior art keywords
methyl
pyrazol
cyano
carboxylate
piperidine
Prior art date
Application number
ARP110104351A
Other languages
English (en)
Inventor
Mascitti Vincent
Pelton Robinson Ralph
Francis Mclure Kim
John Munchhof Michael
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45418722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR088121(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AR088121A1 publication Critical patent/AR088121A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos que modulan la actividad del receptor GPR119 acoplado a la proteína G y sus usos para el tratamiento de enfermedades relacionadas con la modulación del receptor GPR119 acoplado a la proteína G en animales. Reivindicación 1: Un compuesto caracterizado porque es seleccionado del grupo que consiste de: 4-{5-ciano-4-[(2,4-difluorofenoxi)metil]-1H-pirazol-1-il}piperidin-1-carboxilato de isopropilo; 4-{5-ciano-4-[(2-metilfenoxi)metil]-1H-pirazol-1-il}piperidin-1-carboxilato de isopropilo; 4-{5-ciano-4-[(2,5-difluorofenoxi)metil]-1H-pirazol-1-il}piperidin-1-carboxilato de 1-metilciclopropilo; 4-{5-ciano-4-[(2,3-difluorofenoxi)metil]-1H-pirazol-1-il}piperidin-1-carboxilato de 1-metilciclopropilo; 4-{4-[(4-carbamoil-2-fluorofenoxi)metil]-5-ciano-1H-pirazol-1-il}piperidin-1-carboxilato de 1-metilciclopropilo; 4-{4-[(4-carbamoilfenoxi)metil]-5-ciano-1H-pirazol-1-il}piperidin-1-carboxilato de 1-metilciclopropilo; 4-(5-ciano-4-((4-cianofenoxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-(4-((4-(1H-pirazol-1-il)fenoxi)metil)-5-ciano-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-((2-fluoro-4-(1H-tetrazol-5-il)fenoxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo y 4-(5-ciano-4-((2-fluoro-4-(2H-tetrazol-5-il)fenoxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-((2-fluoro-4-(1-metil-1H-tetrazol-5-il)fenoxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-((2-fluoro-4-(2-metil-2H-tetrazol-5-il)fenoxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-((2-fluoro-4-(2-(2-hidroxietil)-2H-tetrazol-5-il)fenoxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-((2-fluoro-4-(1-(2-hidroxietil)-1H-tetrazol-5-il)fenoxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-{[2-fluoro-4-(1-metil-1H-tetrazol-5-il)fenoxi]metil}-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-(5-ciano-4-{[4-(1-metil-1H-tetrazol-5-il)fenoxi]metil}-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-(4-((4-carbamoil-3-fluorofenoxi)metil)-5-ciano-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-(5-ciano-4-{1-[2-fluoro-4-(metilsulfonil)fenoxi]etil}-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-{1-[(2-metilpiridin-3-il)oxi]etil}-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-{2-[2-fluoro-4-(metilsulfonil)fenil]propil}-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-{[(2-metilpiridin-3-il)oxi]metil}-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-{5-ciano-4-[(2,3,6-trifluorofenoxi)metil]-1H-pirazol-1-il}piperidin-1-carboxilato 1-metilciclopropilo; 4-{5-ciano-4-[(2,3,6-trifluorofenoxi)metil]-1H-pirazol-1-il}piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-{{2-fluoro-4-(1-metil-1H-imidazol-2-il)fenoxi]metil}-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-{[2-fluoro-4-(1-metil-1H-imidazol-5-il)fenoxi]metil}-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-[5-ciano-4-({[2-metil-6-(1H-1,2,4-triazol-1-il)piridin-3-il]oxi}metil)-1H-pirazol-1-il]piperidin-1-carboxilato de isopropilo; 4-[5-ciano-4-({[2-metil-6-(1H-1,2,4-triazol-1-il)piridin-3-il]amino}metil)-1H-pirazol-1-il]piperidin-1-carboxilato de isopropilo; 4-[5-ciano-4-({[2-metil-6-(metilsulfonil)piridin-3-il]amino}metil)-1H-pirazol-1-il]piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-{[4-(1H-tetrazol-1-il)fenoxi]metil}-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 1-[1-(5-etilpirimidin-2-il)piperidin-4-il]-4-{[4-(1H-tetrazol-1-il)fenoxi]metil}-1H-pirazol-5-carbonitrilo; 4-{5-ciano-4-[(3-cianofenoxi)metil]-1H-pirazol-1-il}piperidin-1-carboxilato de isopropilo; 4-{5-ciano-4-[(4-ciano-3-metilfenoxi)metil]-1H-pirazol-1-il}piperidin-1-carboxilato de isopropilo; 4-{5-ciano-4-[(4-cianofenoxi)metil]-1H-pirazol-1-il}piperidin-1-carboxilato de isopropilo; 4-[(4-ciano-2-fluorofenoxi)metil)-1-[1-(5-etilpirimidin-2-il)piperidin-4-il]-1H-pirazol-5-carbonitrilo; 4-{5-ciano-4-[(4-ciano-2-fluorofenoxi)metil)-1H-pirazol-1-il}piperidin-1-carboxilato de ter-butilo; 4-{5-ciano-4-[(2-ciano-4-fluorofenoxi)metil]-1H-pirazol-1-il}piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-{[4-(dimetilcarbamoil)-2-fluorofenoxi]metil}-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-{[4-(dimetilcarbamoil)-2-fluorofenoxi]metil}-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-(5-ciano-4-{[2-fluoro-4-(metilcarbamoil)fenoxi]metil}-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-({5-ciano-1-[1-(5-etilpirimidin-2-il)piperidin-4-il]-1H-pirazol-4-il}metoxi)-3-fluoro-N,N-dimetilbenzamida; 4-{5-ciano-4-[(4-ciano-2-fluorofenoxi)metil]-1H-pirazol-1-il}piperidin-1-carboxilato de 1-metilciclopropilo; (3S,4S)-4-(5-ciano-4-{[2-fluoro-4-(metilcarbamoil)fenoxi]metil}-1H-pirazol-1-il)-3-fluoropiperidin-1-carboxilato de ter-butilo; (3R,4S)-4-(5-ciano-4-{(2-fluoro-4-(metilcarbamoil)fenoxi]metil}-1H-pirazol-1-il)-3-fluoropiperidin-1-carboxilato de ter-butilo; (3S,4S)-4-(5-ciano-4-{[2-fluoro-4-(metilcarbamoil)fenoxi]metil}-1H-pirazol-1-il)-3-fluoropiperidin-1-carboxilato de 1-metilciclopropilo; (3R,4R)-4-(5-ciano-4-{[2-fluoro-4-(metilcarbamoil)fenoxi]metil}-1H-pirazol-1-il)-3-fluoropiperidin-1-carboxilato de 1-metilciclopropilo; (3S,4S)-4-(5-ciano-4-{[(2-metilpiridin-3-il)oxi]metil}-1H-pirazol-1-il)-3-fluoropiperidin-1-carboxilato de ter-butilo; (3S,4R)-4-(5-ciano-4-{[(2-metilpiridin-3-il)oxi]metil}-1H-pirazol-1-il)-3-fluoropiperidin-1-carboxilato de ter-butilo; (3S,4R)-4-(5-ciano-4-{[(2-metilpiridin-3-il)oxi]metil}-1H-pirazol-1-il)-3-fluoropiperidin-1-carboxilato de 1-metilciclopropilo; (3S,4R)-4-(5-ciano-4-{[(2-metilpiridin-3-il)oxi]metil}-1H-pirazol-1-il)-3-fluoropiperidin-1-carboxilato de 1-metilciclopropilo; (3R,4S)-4-(5-ciano-4-{[(2-metilpiridin-3-il)oxi]metil}-1H-pirazol-1-il)-3-fluoropiperidin-1-carboxilato de 1-metilciclopropilo; 4-(5-ciano-4-{(4-(1H-1,2,3-triazol-1-il)fenoxilmetil}-1H-pirazol-1-il)piperidin-1-carboxilato de ter-butilo; 4-(5-ciano-4-{[4-(2H-1,2,3-triazol-2-il)fenoxi]metil}-1H-pirazol-1-il)piperidin-1-carboxilato de ter-butilo; 4-(4-((4-(1H-1,2,3-triazol-1-il)fenoxi)metil)-5-ciano-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-(4-((4-(2H-1,2,3-triazol-2-il)fenoxi)metil)-5-ciano-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-[5-ciano-4-({[1-(metilsulfonil)piperidin-4-il]oxi}metil)-1H-pirazol-1-il]piperidin-1-carboxilato de ter-butilo; 4-[5-ciano-4-({2-fluoro-4-[(2-hidroxietil)(metil)carbamoil]fenoxi}metil)-1H-pirazol-1-il]piperidin-1-carboxilato de ter-butilo; 4-[5-ciano-4-({2-fluoro-4-[(3-hidroxipirrolidin-1-il)carbonil]fenoxi}metil)-1H-pirazol-1-il]piperidin-1-carboxilato de ter-butilo; 4-(4-{[4-(azetidin-1-ilcarbonil)-2-fluorofenoxi]metil}-5-ciano-1H-pirazol-1-il)piperidin-1-carboxilato de ter-butilo; 4-[5-ciano-4-({[1-(metilsulfonil)piperidin-4-il]oxi}metil)-1H-pirazol-1-il]piperidin-1-carboxilato de 1-metilciclopropilo; 4-(5-ciano-4-((2-fluoro-4-(1H-1,2,3-triazol-1-il)fenoxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-(5-ciano-4-((2-fluoro-4-(1H-1,2,3-triazol-1-il)fenoxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 1-(1-(5-etilpirimidin-2-il)piperidin-4-il)-4-((2-fluoro-4-(1H-1,2,3-triazol-1-il)fenoxi)metil)-1H-pirazol-5-carbonitrilo; 4-(4-((4-(1H-1,2,3-triazol-1-il)fenoxi)metil)-5-ciano-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-((4-(1H-1,2,3-triazol-1-il)fenoxi)metil)-1-(1-(5-etiIpirimidin-2-il)piperidin-4-il)-1H-pirazol-5-carbonitrilo; 4-(4-((4-(2H-1,2,3-triazol-2-il)fenoxi)metil)-5-ciano-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-((4-(2H-1,2,3-triazol-2-il)fenoxi)metil)-1-(1-(5-etilpirimidin-2-il)piperidin-4-il)-1H-pirazol-5-carbonitrilo; 4-(5-ciano-4-((2-fluoro-4-(2H-1,2,3-triazol-2-il)fenoxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-(5-ciano-4-((2-fluoro-4-(2H-1,2,3-triazol-2-il)fenoxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 1-(1-(5-etilpirimidin-2-il)piperidin-4-il)-4-((2-fluoro-4-(2H-1,2,3-triazol-2-il)fenoxi)metil)-1H-pirazol-5-carbonitrilo; 4-(4-((5-(1H-1,2,3-triazol-1-il)piridin-2-iloxi)metil)-5-ciano-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-(4-((5-(1H-1,2,3-triazol-1-il)piridin-2-iloxi)metil)-5-ciano-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-((3-fluoro-4-(1H-tetrazol-1-il)fenoxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-(5-ciano-4-((3-fluoro-4-(1H-tetrazol-1-il)fenoxi)metil)-1H-pirazol-1-il)piperidin-1- carboxilato de isopropilo; 1-(1-(5-etilpirimidin-2-il)piperidin-4-il)-4-((3-fluoro-4-(1H-tetrazol-1-il)fenoxi)metil)-1H-pirazol-5-carbonitrilo; 4-((5-(1H-1,2,3-triazol-1-il)piridin-2-iloxi)metil)-1-(1-(5-etilpirimidin-2-il)piperidin-4-il)-1H-pirazol-5-carbonitrilo; 1-(1-(5-etilpirimidin-2-il)piperidin-4-il)-4-((2-metil-6-(1H-1,2,3-triazol-1-il)piridin-3-iloxi)metil)-1H-pirazol-5-carbonitrilo; 4-(5-ciano-4-((2-metil-6-(1H-1,2,3-triazol-1-il)piridin-3-iloxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; 4-(5-ciano-4-((2-metil-6-(1H-1,2,3-triazol-1-il)piridin-3-iloxi)metil)-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 1-(1-(5-etilpirimidin-2-il)piperidin-4-il)-4-((2-fluoro-4-(1-metil-1H-tetrazol-5-il)fenoxi)metil)-1H-pirazol-5-carbonitrilo; 1-(4-((4-(azetidin-1-carbonil)-2-fluorofenoxi)metil)-5-ciano-1H-pirazol-1-il)piperidin-1-carboxilato de 1-metilciclopropilo; 4-(4-((4-(azetidin-1-carbonil)-2-fluorofenoxi)metil)-5-ciano-1H-pirazol-1-il)piperidin-1-carboxilato de isopropilo; y 4-((4-(azetidin-1-carbonil)-2-fluorofenoxi)metil)-1-(1-(5-etilpirimidin-2-il)piperidin-4-il)-1H-pirazol-5-carbonitrilo; o una sal de este aceptable desde el punto de vista farmacéutico.
ARP110104351A 2010-11-23 2011-11-22 Derivados de 4-(5-ciano-pirazol-1-il)-piperidina como moduladores de gpr119 AR088121A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41644110P 2010-11-23 2010-11-23

Publications (1)

Publication Number Publication Date
AR088121A1 true AR088121A1 (es) 2014-05-14

Family

ID=45418722

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104351A AR088121A1 (es) 2010-11-23 2011-11-22 Derivados de 4-(5-ciano-pirazol-1-il)-piperidina como moduladores de gpr119

Country Status (26)

Country Link
EP (1) EP2643310A1 (es)
JP (1) JP2013543885A (es)
KR (1) KR20130083915A (es)
CN (1) CN103298801A (es)
AP (1) AP2013006809A0 (es)
AR (1) AR088121A1 (es)
AU (1) AU2011333427A1 (es)
BR (1) BR112013011865A2 (es)
CA (1) CA2814231A1 (es)
CL (1) CL2013001054A1 (es)
CO (1) CO6801716A2 (es)
CR (1) CR20130139A (es)
CU (1) CU20130059A7 (es)
DO (1) DOP2013000102A (es)
EA (1) EA201370118A1 (es)
EC (1) ECSP13012630A (es)
GT (1) GT201300135A (es)
MA (1) MA34805B1 (es)
MX (1) MX2013004083A (es)
NI (1) NI201300044A (es)
PE (1) PE20140409A1 (es)
SG (1) SG189830A1 (es)
TW (1) TWI433843B (es)
UY (1) UY33742A (es)
WO (1) WO2012069948A1 (es)
ZA (1) ZA201302362B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6463631B2 (ja) 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Ｇｐｒ−１１９のモジュレータとしての新規化合物
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
CN104892517A (zh) * 2015-02-13 2015-09-09 佛山市赛维斯医药科技有限公司 酰肼类化合物、其制备方法及用途
CN104610151A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 含酰肼和烷氧苯类结构的化合物、其制备方法及用途
CN104592120A (zh) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和甲氧苯类gpr119激动剂、制备方法及其用途
EP3416959B1 (en) 2016-02-18 2021-05-12 Syngenta Participations AG Pesticidally active pyrazole derivatives
CN106631992B (zh) * 2017-01-05 2019-01-18 桑迪亚医药技术（上海）有限责任公司 一种4-氧-3,4-二氢-2h-吡啶-1-甲酸叔丁酯的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185544B1 (en) * 2007-07-19 2014-11-26 Cymabay Therapeutics, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders
TW201002705A (en) * 2008-03-31 2010-01-16 Metabolex Inc Oxymethylene aryl compounds and uses thereof
NZ596467A (en) * 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators

Also Published As

Publication number Publication date
MA34805B1 (fr) 2014-01-02
NI201300044A (es) 2013-08-01
CA2814231A1 (en) 2012-05-31
SG189830A1 (en) 2013-06-28
PE20140409A1 (es) 2014-03-23
UY33742A (es) 2012-06-29
AU2011333427A1 (en) 2013-04-11
CR20130139A (es) 2013-06-28
EP2643310A1 (en) 2013-10-02
DOP2013000102A (es) 2013-07-15
KR20130083915A (ko) 2013-07-23
CU20130059A7 (es) 2013-06-28
GT201300135A (es) 2015-02-19
MX2013004083A (es) 2013-06-13
WO2012069948A1 (en) 2012-05-31
TWI433843B (zh) 2014-04-11
AP2013006809A0 (en) 2013-04-30
CO6801716A2 (es) 2013-11-29
BR112013011865A2 (pt) 2016-08-23
TW201300373A (zh) 2013-01-01
EA201370118A1 (ru) 2013-12-30
CN103298801A (zh) 2013-09-11
ZA201302362B (en) 2014-06-25
CL2013001054A1 (es) 2013-09-27
JP2013543885A (ja) 2013-12-09
ECSP13012630A (es) 2013-07-31

Similar Documents

Publication Publication Date Title
AR088121A1 (es) Derivados de 4-(5-ciano-pirazol-1-il)-piperidina como moduladores de gpr119
RU2425838C2 (ru) Ингибиторы iap
RU2396269C2 (ru) Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1)
HRP20120240T1 (hr) Piridil piperidin antagonisti receptora za oreksin
HRP20160421T1 (hr) Derivat azola
HRP20150355T1 (hr) Sulfonamidni derivati
SI2855449T1 (en) SULFONYL PIPERIDIN DERIVATIVES AND THEIR USE IN TREATMENT OF PROKINETICINAL DISEASE DISEASES
HRP20160172T1 (hr) Spojevi koji su inhibitori metaloenzima
EA023517B1 (ru) Модуляторы глюкагонового рецептора
AR064302A1 (es) Arilpirazoles sustitudos
NZ595073A (en) Proline derivatives as cathepsin inhibitors
JP2008513405A5 (es)
NZ592792A (en) Heterocyclically substituted aryl compounds as hif inhibitors
RU2006127572A (ru) Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
JP2007523181A5 (es)
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
JP2007502821A5 (es)
JP2007530690A5 (es)
JP2014514299A5 (es)
AR098031A1 (es) Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida
JP2013507366A5 (es)
ES2557478T3 (es) Compuestos de pirazol y triazol como inhibidores de KSP
CA2592986A1 (en) Heteroaromatic quinoline compounds
JP2013523819A5 (es)
JP2007519717A5 (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal